Immediate release fixed dose combination product [Regulatives / Guidelines]

posted by Dr_Dan  – Germany, 2020-03-11 12:47 (1503 d 21:49 ago) – Posting: # 21240
Views: 4,373

Hello ping4santosh,
Even if you aim at substitution indication (improvement of patient's compliance) presenting co-prescription data and therapeutic guidelines recommending the co-administration will not suffice as long as you are unable to present clinical data demonstrating safety and efficacy of the respective combination. IMHO it will be hard to identify a new FDC which can be approved without a phase III study (at least in western Europe).

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
22,990 posts in 4,826 threads, 1,664 registered users;
60 visitors (0 registered, 60 guests [including 1 identified bots]).
Forum time: 11:37 CEST (Europe/Vienna)

If you don’t like something change it;
if you can’t change it, change the way you think about it.    Mary Engelbreit

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5